Ryoma Kani

Ryoma Kani

Auto-generated profile, based on publicly available information

Ryoma Kani

Postgraduate Education Center Kameda Medical Center Kamogawa‐shi Chiba Japan

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
RKRyoma Kani
Ryoma Kani
AWAtsuyuki Watanabe
Atsuyuki Watanabe
YMYoshihisa Miyamoto
Yoshihisa Miyamoto
KEKentaro Ejiri
Kentaro Ejiri
MIMasao Iwagami
Masao Iwagami
TKToshiki Kuno
Toshiki Kuno
Background: To investigate the individual profile of each SGLT2 (sodium‐glucose cotransoporter‐2) inhibitor in patients with different backgrounds. Methods and Results: This study included 21 placebo‐controlled randomized controlled trials with a total of 96 196 participants, investigating empagliflozin, ertugliflozin, dapagliflozin, canagliflozin, and sotagliflozin. The primary efficacy end point was the composite of cardiovascular death and hospitalizations for heart failure. The secondary efficacy end points were all‐cause death, cardiovascular death, hospitalizations for heart failure, kidney disease progression, and acute kidney injury. We conducted subgroup analyses based on the underlying comorbidities, including diabetes and chronic kidney disease. Safety end points were also assessed among SGLT2 inhibitors in the overall cohort. In the overall cohort, there were no significant differences in the primary efficacy outcome among the SGLT2 inhibitors, while empagliflozin (hazard ratio [HR], 0.70 [95% CI, 0.53–0.92]) and dapagliflozin (HR, 0.73 [95% CI, 0.56–0.96]) were associated with lower risk of acute kidney injury than sotagliflozin. The presence or absence of diabetes did not alter the results. In patients with chronic kidney disease, there were no differences in the efficacy outcomes among SGLT2 inhibitors, while in patients without chronic kidney disease, empagliflozin was associated with lower risk of the primary outcome compared with ertugliflozin (HR, 0.77 [95% CI, 0.60–0.98]). For safety outcomes, no significant differences were observed in amputation, urinary tract infection, genital infection, hypoglycemia, and diabetic ketoacidosis. Conclusions: The differences in reducing cardiovascular and kidney outcomes as well as safety profiles across SGLT2 inhibitors were not consistently significant, although empagliflozin might be preferred in patients without chronic kidney disease. Further investigations are needed to better understand the mechanism and clinical effectiveness of each SGLT2 inhibitor in certain populations.

3 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
RKRyoma Kani
Ryoma Kani
TKTony Kaku
Tony Kaku
YAYu Arai
Yu Arai
TETakahide Etani
Takahide Etani
SHSunjun Huh
Sunjun Huh
SNShinichiro Nakajima
Shinichiro Nakajima
Metabotropic glutamate receptors (mGluRs) regulate glutamatergic transmission and have been implicated in diverse neuropsychiatric disorders, but human postmortem evidence remains fragmented. We aimed to map these findings across diagnoses, receptor subtypes, brain regions, and measurement modalities. Following PRISMA guidelines, we systematically searched MEDLINE, EMBASE, and Web of Science from inception to August 8, 2026, for studies assessing GRM transcripts, as well as mGluR protein abundance, localization, assembly, or receptor binding in human postmortem brain tissue. Of 532 records identified, 57 reports met eligibility criteria. Findings were synthesized narratively because of substantial heterogeneity in diagnoses, brain regions, receptor subtypes, and assays. Postmortem evidence was concentrated on mGluR5, mGluR2/3, and mGluR1, and on the prefrontal cortex, anterior cingulate cortex, and hippocampus. mGluR-related alterations were reported across disorders, including schizophrenia, major depressive disorder, Alzheimer disease, autism spectrum disorder, and alcohol use disorder. Although most analyses yielded null findings, the direction and magnitude of mGluR alterations varied across brain regions, receptor subtypes, and molecular endpoints. This inconsistency may partly reflect the distinct biological levels captured by transcript abundance, total protein, receptor assembly, localization, and ligand binding, together with regional, cell-type, disease-stage, and clinical heterogeneity. The available evidence therefore suggests context-dependent alterations in mGluR biology but not a uniform or disorder-specific molecular signature. Integration of postmortem findings with other approaches, including in vivo imaging, may clarify their biological and clinical significance.

30 April 2026 in Neuropsychopharmacology Reports
Verified
Journal Article
Open access
TETakahide Etani
Takahide Etani
NHNobuaki Hondo
Nobuaki Hondo
SMSho Moriguchi
Sho Moriguchi
KYKazunari Yoshida
Kazunari Yoshida
SMSotaro Moriyama
Sotaro Moriyama
SNShinichiro Nakajima
Shinichiro Nakajima
Recently, an increasing number of studies have reported abnormal levels of glutathione (GSH)‐related metabolites and enzyme activities in neuroimaging and peripheral samples in patients with depression, indicating abnormalities in the GSH cycle in patients with depression. However, the abnormalities in the GSH cycle have not been comprehensively investigated. Here, we conducted a systematic review and meta‐analysis to compare the levels of GSH‐related metabolites (GSH and GSH disulfide [GSSG]) and the activities of GSH‐related enzymes (Glutathione‐peroxidase [GPx], GSH reductase [GR], glutamate‐cysteine ligase [GCL], GSH synthetase [GS], and GSH S‐transferase [GST]) between patients with depression and healthy controls (HC). The search was performed with MEDLINE, Embase, and PsychINFO. The inclusion criteria were studies comparing levels of GSH‐related metabolites and enzyme activities between patients with depression and HC. Standardized mean differences were calculated to assess group differences. Thirty studies met the eligibility criteria, which included 1019 patients and 947 HC. Our meta‐analysis indicated significantly decreased activity of GPx in patients with depression compared with HC, while the levels of GSH and GR were not significantly different between the groups. Because no studies, or an insufficient number of studies, have been conducted on GSSG, GST, GCL, and GS, meta‐analyses were not performed for these metabolites and enzyme activities. Our findings suggest that abnormal cycling of the GSH system, particularly decreased GPx activity, is involved in the pathophysiology of depression and may serve as a potential biomarker for this illness. Furthermore, given that no or insufficient studies have been conducted on GSSG, GST, GCL, and GS, this study highlights the need for further research to fully elucidate the GSH cycle in patients with depression.

10 August 2025 in Psychiatry and Clinical Neurosciences Reports
Verified
Journal Article
Open access
RKRyoma Kani
Ryoma Kani
HGHidehiro Gon
Hidehiro Gon
SNShinichiro Nakajima
Shinichiro Nakajima
KYKazunari Yoshida
Kazunari Yoshida